SCHEMBL4059124

SCHEMBL4059124

CC(C)Oc1cccc(-c2nc3ncc(Br)cc3[nH]2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 5/20 0.53
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
PAK4 O96013 1/20 0.46
TBK1 Q9UHD2 1/20 0.44
HDAC6 Q9UBN7 1/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.41
ESR1 P03372 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
CBFB Q13951 1/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054551 0.89 AURKA (0.49) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4054555 0.86 AURKA (0.67) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4058280 0.86 AURKA (0.50) AURKATBK1GABRA1GABRG2GABRB3
SCHEMBL4058201 0.84 SMN1; SMN2 (0.55) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4236251 0.84 SMN1; SMN2 (0.50) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4053786 0.84 AURKA (0.60) AURKATBK1NOS3NOS1NOS2
SCHEMBL4050654 0.83 AURKA (0.52) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4055805 0.83 AURKA (0.47) AURKATBK1GABRA1GABRG2GABRB3
SCHEMBL4055350 0.82 SMN1; SMN2 (0.53) AURKASMN1; SMN2LMNAHTTNPSR1
SCHEMBL4054621 0.82 AURKA (0.47) AURKATBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885SMN1; SMN2 4289/4885LMNA 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.